Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a prolonged half-life of approximately 7 days approved for chronic weight management and glycemic control. The extended half-life enables once-weekly subcutaneous dosing, which is the standard clinical approach
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a prolonged half-life of approximately 7 days approved for chronic weight management and glycemic control. The extended half-life enables once-weekly subcutaneous dosing, which is the standard clinical approach